Cellular activity and signaling induced by osteoprotegerin in osteoclasts: involvement of receptor activator of nuclear factor κB ligand and MAPK  by Theoleyre, S et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1644 (2004) 1–7Cellular activity and signaling induced by osteoprotegerin in
osteoclasts: involvement of receptor activator of nuclear
factor nB ligand and MAPK
S. Theoleyrea,1, Y. Wittranta,1, S. Couillauda, P. Vusiob, M. Berreura,
C. Dunstanc, F. Blancharda, F. Re´dinia, D. Heymanna,*
aEE 99-01, Pathophysiology of Bone Resorption Laboratory and Therapy of Primitive Bone Tumors,
Medicine Faculty, 1 rue G. Veil, 44035 Nantes cedex 01, France
b IFR 26, Institut de Biologie, Nantes Hospital, France
cAmgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USAReceived 22 July 2003; received in revised form 19 September 2003; accepted 15 October 2003Abstract
Osteoprotegerin (OPG) is a decoy receptor for receptor activator of nuclear factor nB ligand (RANKL), an inducer of osteoclastogenesis
via its receptor RANK. We recently demonstrated that OPG also exerts a direct effect in osteoclasts by regulating protease expression. Herein,
we showed that OPG-induced pro-matrix metalloproteinase-9 activity was abolished by ras/MAPK inhibitors in purified osteoclasts. OPG
induced the phosphorylation of p38 and ERK1/2 in RAW264.7 cells. Only p38 activation was totally abolished by a blocking anti-RANKL
antibody or an excess of RANKL. Surface plasmon resonance experiments revealed that RANK, RANKL and OPG are able to form a tertiary
complex. These results suggested a potential formation of a tertiary complex RANK–RANKL–OPG on osteoclasts. Thus, OPG is not only a
soluble decoy receptor for RANKL but must be also considered as a direct effector of osteoclast functions.
D 2003 Elsevier B.V. All rights reseved.Keywords: Osteoprotegerin; RANKL; Osteoclast; Metalloproteinase; Signaling1. Introduction
Among the cellular and molecular parameters involved in
the bone resorption process [1–3], receptor activator of
nuclear factor nB ligand (RANKL), a member of the tumor
necrosis factor family is the main regulator of osteoclast
differentiation [4,5]. Within the bone system, soluble and
membrane forms of RANKL expressed by osteoblasts exert
their activities through binding to their receptor RANK on
osteoclasts [6,7]. The third protagonist, osteoprotegerin
(OPG) produced by osteoblasts acts as a decoy receptor
for RANKL, preventing it from binding to and activating0167-4889/$ - see front matter D 2003 Elsevier B.V. All rights reseved.
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1 Equally contributed to the work.RANK [8]. It also inhibits the development of osteoclasts
[9] and down-regulates the RANKL signaling through
RANK [8]. The biological effects of OPG on bone cells
include the inhibition of terminal stages of osteoclast
differentiation, suppression of mature osteoclast activation,
and induction of apoptosis [7–9].
We recently demonstrated that OPG can also exert a
direct biological effect in osteoclasts by inducing proteases
and protease inhibitors expression suggesting a more com-
plex regulation of bone resorption by OPG than originally
described [10]. These results are consistent with those
obtained by Hakeda et al. [11] who reported a direct effect
of OPG on isolated osteoclasts via a 140 kDa OPG-binding
protein on cell membrane. Whereas OPG exhibits no
transmembrane domain, Yun et al. [12] reported the pres-
ence of a membrane-bound form of OPG in dendritic cells
that may correspond to either a matrix-bound or/and a
transmembrane form of the protein. More recently, Standal
et al. presented evidence that myeloma cells internalize and
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heparan sulfate proteoglycan expressed on myeloma cells
[13]. OPG possesses a highly basic heparin-binding domain,
making interactions with heparin and heparan sulfates
possible, suggesting a new control mechanism for OPG
biological activity [14].
The purpose of the present study was (i) to further
investigate the direct biological effect of OPG on osteoclasts
and the signaling pathways associated, (ii) to better charac-
terize the receptor(s) involved.2. Experimental procedures
2.1. Cell culture
2.1.1. Purified osteoclast preparation
Purified osteoclasts (purity 95%) were obtained from
neonatal rabbit bone cells isolated using a previously reported
method [15]. After purification, the osteoclasts were cultured
in serum-free a-MEM for 24 h in the absence or presence of
50 ng/ml human OPG (Amgen Inc., Thousand Oaks, USA).
In some experiments, before addition of OPG, cells were also
preincubated for 1 h in the presence of signaling pathway
inhibitors: PI 3 kinase (Wortmannin: 500 nM), tyrosine
kinase (Genistein: 200 AM) (Saint Quentin Fallavier, France),
protein kinase A (PKI 5–24: 100 nM), PKC and cAMP-
dependent protein kinase (H7 dihydrochloride: 100 AM),
MAPK extracellular signaling-regulated kinase (ERK) ki-
nase (MEK) (PD98059: 40 AM), Ras (FPT inhibitor II
(FPTII): 40 AM) and p38 MAPK (SB203580: 0.1, 10 AM)
(Calbiochem, La Jolla, USA). Equivalent dilutions of DMSO
(reconstitution solution) alone served as control. A dose–
response of the different inhibitors was tested previously and
the optimal doses were used in this study.
The RAW264.7 cells obtained from Prof. Matsumoto
(Saitama, Japan) were maintained in a-MEM without red
phenol supplemented with 10% FBS and differentiated in
the presence of 50 ng/ml human RANKL (Amgen) for 10
days. Cells were then cultured in serum-free medium for 24
h and incubated for 5 min in the presence or absence of 50
ng/ml RANKL or OPG, with or without 4 Ag/ml anti-human
RANKL antibody (R&D System, Abington, UK). In some
cases, after serum-free culture period, cells were treated with
50 ng/ml RANKL for 2 h, washed or not before incubation
with the combinations described above.
The 293 cells transfected with the full-length cDNA
coding for murine RANKL (293-RANKL cells) were a
generous gift of Dr. R. Josien (INSERM U437, Nantes,
France) and were cultured in DMEM supplemented with
10% FBS.
2.1.2. Measurement of matrix metalloproteinase activities
After 3 days of culture ina-MEM supplemented with 10%
FBS, purified osteoclasts were cultured for 24 h in serum-free
a-MEM in the presence or absence of 50 ng/ml OPG. Matrixmetalloproteinase (MMP) activities were then detected in cell
culture supernatants by gelatin zymography as previously
described [15]. After the culture period (24 h in serum-free a-
MEM in the presence or absence of OPG), MMP activities
were detected in cell culture supernatants. Electrophoresis gel
was composed of 10% polyacrylamide gel containing 0.2%
gelatin. Proteinase activity was apparent as unstained
regions. The stained polyacrylamide gels were observed with
a video camera that allowed transfer to software for image
processing (ImageQuant software program) and isolation of
migration bands. Gelatinase activity was expressed as a
percentage (shades of grey compared to the control). The
same experiment was performed by adding 10 AM EDTA, a
chelating agent of bivalent ions, to inhibit MMP activities. In
addition, as protein levels were not modified by the different
treatments, the same volume of supernatant was assayed in all
experiments, allowing strict comparison of the results.
2.1.3. Semi-quantitative reverse transcription-polymerase
chain reaction (RT-PCR)
Total RNA for cDNA synthesis was isolated from
RAW264.7 cells and 293-RANKL cells by phenol–chloro-
form extraction as previously described [12]. RT-PCR assays
were carried out using the following primer pairs for RANKL
(5V-CAGCATCGCTCTGTTCCTGTA-3 (sense), 5V-
TCTCAGTCTATGCCTGAACTTTGAAAGC-3V (anti-
sense)); RANK (5V-AAGATGGTTCCAGAAGACGGT-3V
(sense), 5V-CATAGAGTCAGTTCTGCTCGGA-3V);
MMP-9 (5V-TCTGAGGCCTCTACAGAGTCT-3V (sense),
5V-CTCATGGTCCACCTTGTTCAC-3V (antisense)) and
18S (5V-TCAAGAACGAAAGTCGGAGGTTCG-3V
(sense) and 5V-TTATTGCTCAATCTCGGGTGGCTG-3V
(antisense)).
2.1.4. Western blot studies and signal transduction
RAW264.7 cells were lysed in ice-cold lysis buffer (NaCl
150 mM, Tris 50 mM, Nonidet P-40 1%, sodium deoxy-
cholate 0.25%, NaF 1 mM, NaVO4 1 mM, leupeptine 10 Ag/
ml, aprotinin 10 Ag/ml, phenymethylsulfonylfluoride 0.5
mM, glycerol 10%). Equal amounts of proteins were re-
solved on 10% SDS-PAGE, and transferred to a PVDF
membrane. After two washes in 0.05% Tween 20/PBS, the
membrane was incubated in a saturating solution (0.05%
Tween 20/3% BSA/PBS) for 30 min, the levels of phos-
phorylated ERK1/2 and p38 were detected with specific
antibodies (Ozyme Saint-Quentin en Yvelines, France) as
well as total ERK1/2 and p38 (R&D System).
2.1.5. Surface plasmon resonance studies
These experiments were performed with the BIACore
2000 optical biosensor (BIACore, Uppsala, Sweden). Solu-
ble human RANK (sRANK) (Promocell, Heidelberg, Ger-
many) was covalently coupled through its primary amino
groups to a carboxymethyl dextran flow cell (CM5, BIA-
Core) as recommended by the manufacturer. All binding
experiments were performed at a flow rate of 10 Al/min. The
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subtracted from the signal measured on the experimental
flow cell. The resulting sensorgrams were analyzed using
the BIAEvaluation software (BIACore).
2.1.6. Statistical analysis
The meanF S.D. was calculated for all conditions and
compared by ANOVA. Differences relative to a probability
of two-tailed P < 0.05 were considered significant.Fig. 1. Inhibition of OPG-induced proMMP-9 activity on purified
osteoclasts by ras/MAPK inhibitors. Purified osteoclasts were cultured in
the absence or presence of 50 ng/ml OPG, in association or not with
different signaling pathway inhibitors: Genistein 200 AM (tyrosine kinase
inhibitor), H7 100 AM (PKC- and cAMP-dependent protein kinase
inhibitor), FPTII 40 AM (Ras inhibitor) (A) or PD98059 40 AM (MEK
inhibitor), SB203580 0.1 and 10 AM (p38 inhibitor) (B). Metalloproteinase
activity was determined using a gelatin zymographic assay. Results are the
meanF S.D. of five separate cultures tested. **P < 0.001 ***P < 0.0001
compared to OPG alone, #P < 0.05 compared to the untreated control.3. Results
3.1. OPG enhances proMMP-9 activity of purified osteo-
clasts by the ras/MAPK pathway
To determine the signaling pathways by which OPG
exerts its effects on osteoclasts, the modulation of OPG-
induced proMMP-9 activities was studied in the presence of
specific inhibitors of different intracellular signaling path-
ways. Tyrosine kinase inhibitor (Genistein), PKC and
cAMP-dependent protein kinase inhibitor (H7) and Ras
inhibitor (FPT inhibitor II) completely abolished OPG-
induced stimulation of proMMP-9 (Fig. 1A). Conversely,
PI 3 kinase inhibitor (Wortmannin) and protein kinase A
inhibitor (PKI 5–24) did not prevent OPG effects (data not
shown). In this context, two synthetic MAPK inhibitors
(SB203580 and PD98505 inhibitors of p38 and MEK,
respectively) have been studied (Fig. 1B). Thus, pretreat-
ment with SB203580 inhibited the OPG-induced proMMP-
9 activity in a dose-dependent manner. Similarly, 40 AM of
PD98059 completely abolished the OPG-induced proMMP-
9 activity. Both inhibitors did not affect pro-MMP-9 activity
of non-stimulated osteoclasts (not shown). These results
demonstrated that the ras/MAPK signaling is required for
OPG to stimulate osteoclast proMMP-9 activity.
3.2. OPG induces phosphorylation of ERK1/2 and p38 in
differentiated RAW264.7 cells
To further explore the MAPK involvement in cellular
activities induced by OPG on osteoclasts, we employed the
RAW264.7 cells. Indeed, this cell line is known to express
RANK and differentiate into tartrate-resistant acid phospha-
tase (TRAP) and calcitonin receptor-positive cells when
cultured in the presence of RANKL [16]. Moreover, the
large amounts of cellular materials obtained from
RAW264.7 cell cultures allow to perform signal transduc-
tion studies which were impossible on purified osteoclasts.
RAW264.7 cells were differentiated in the presence of
RANKL for 10 days and then RANKL- and serum-de-
prived for 24 h. OPG signaling studies were then monitored
on by Western blot analyses using phosphospecific anti-
bodies. Interestingly, treatment with 50 ng/ml OPG caused
phosphorylation of ERK1/2 (Fig. 2A) and p38 (Fig. 2B)
detectable within 2 min, whereas total ERK1/2 and p38were unchanged. The phosphorylation of ERK1/2 induced
by OPG reached maximum after 5–10 min and thereafter
gradually slightly decreased (Fig. 2A). The phosphorylation
of p38 reached maximum after 10 min (Fig. 2B). We
confirmed that differentiated RAW264.7 cells expressed
RANK (Fig. 3A, lane 3) but not RANKL (Fig. 3A, lane
2) mRNA transcripts as compared to a positive control
(293-RANKL cells, Fig. 3A, lane 1). Since RANKL is
known to activate similar signaling pathways [16,17], we
conducted same experiments in the presence of RANKL
and confirmed the ability of RANKL to induce both ERK1/
2 and p38 MAPKs activation in RAW264.7 cells (Fig. 3B,
lane 3 compared to the control lane 1). Since (i) OPG was
classically described as one of the ligands for RANKL and
(ii) RAW264.7 cells have been differentiated in the pres-
ence of 50 ng/ml of soluble RANKL, similar experiments
were performed in the presence of anti-RANKL antibody,
to test the hypothesis that OPG could act on osteoclasts via
Fig. 3. OPG-induced phosphorylation of ERK1/2 but not p38 is dependent
on RANKL in RAW264.7 cells. (A) RT-PCR analyses of RANK, RANKL
and 18S message levels were performed in RAW264.7 cells and in 293-
RANKL cells. RNA were isolated from RAW264.7 cells differentiated 10
days in the presence of 50 ng/ml RANKL. Lane 1: RT-PCR reaction for
RANKL on a positive control (293-RANKL cells); RT-PCR reactions on
RAW264.7 cells for RANKL (lane 2) and for RANK (lane 3). (B) ERK1/2
and p38 phosphorylation was analyzed on differentiated RAW264.7 cells
treated for 10 min with 50 ng/ml RANKL or OPG in the presence or
absence of 4 Ag/ml blocking anti-RANKL antibody. (C) The OPG-induced
p38 activation was analyzed in the presence of absence of free RANKL
excess and blocking anti-RANKL antibody. Cell lysates were also subjected
to Western blot analysis with anti-ERK1/2 and/or anti-p38 antibodies to
demonstrate equal loading (B and C).
Fig. 2. OPG induced phosphorylation of ERK1/2 and p38 in RAW264.7
cells. RAW264.7 cells were treated with 50 ng/ml OPG and collected after
the indicated time, followed by immunoblotting using anti-phospho-ERK1/
2 (A) or -p38 (B). Cell lysates were also subjected to Western blot analysis
with anti-ERK1/2 and anti-p38 antibodies to demonstrate equal loading.
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OPG-induced phosphorylation of p38 but only slightly
inhibited the activation of ERK1/2 (Fig. 3B, lane 4 com-
pared to the OPG condition lane 2). To elucidate the role of
RANKL in OPG-induced biological activity, p38 activation
was monitored on differentiated RAW264.7 cells that were
RANKL- and serum-deprived for 24 h and then further
treated with RANKL for 2 h. In the first approaches, exten-
sive washing were done before signaling analysis to remove
free RANKL excess but potentially not specific RANKL
bound to membrane RANK. When the RAW264.7 cells are
not rinsed, the excess of free RANKL abolished the OPG-
induced p38 phosphorylation (Fig. 3C, lanes 1 and 2). This
OPG-induced p38 activation persisted when free RANKL
was removed before OPG treatment (cell cultures washed)
(Fig. 3C, lane 3 compared to the control lane 1) and was
totally inhibited by the addition of blocking anti-RANKL
antibody (Fig. 3C, lane 4 compared to the OPG condition
lane 3). Biological activity of OPG on MMP-9 expression
was also totally abolished in the presence of blocking anti-
RANKL antibody (data not shown). These overall results
showed that OPG exerts a cellular activity dependent on the
presence of RANKL associated with osteoclasts, demon-
strating that OPG is not only a soluble decoy receptor for
RANKL as described in the literature [4].
3.3. OPG, RANKL and RANK are able to form a hetero-
molecular complex
As the above results demonstrated, a biological effect of
OPG on osteoclasts, dependent on the presence of RANKL,
and as RANKL is the natural ligand of RANK [7], we
wondered whether OPG could bind to the complex
RANKL–RANK present at the osteoclast membrane. Weinvestigated the molecular interactions between OPG,
RANKL and RANK by surface plasmon resonance tech-
nique. We confirmed that RANKL bound to immobilized
RANK (Fig. 4A,B). Analyses of the kinetic association and
dissociation curves allowed the calculation of the dissociation
constant Kd = 2.05 nM. While OPG did not bind to immobi-
lized RANK (Fig. 4B), it bound to the preformed RANKL–
RANK complex with a Kd = 5.2 nM (Fig. 4A), then consti-
Fig. 4. Formation of a hetero-molecular complex between RANK, RANKL,
and OPG studied by surface plasmon resonance experiments. Binding of
250 nM (7.75 Ag/ml) (A) or 125 nM (3.87 Ag/ml) (B) RANKL and 110 nM
(10 Ag/ml) OPG successively (A) or after pre-incubation for 1 h at 37 jC
(B) to RANK was carried out. Schematic diagrams of RANK–RANKL–
OPG molecular interactions is shown in (C). Trimer RANKL can bind to
the trimer RANK expressed on the osteoclast cell membrane (left), then
inducing specific signal transduction (arrow). Dimer OPG could interact on
the RANKL–RANK complex to form a tertiary complex that could
activate two different signal transduction pathways via this tertiary complex
and an undermined molecule (?) (middle). OPG acts as a decoy receptor
when it is preincubated with RANKL (right).
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Moreover, the preincubation of OPGwith RANKL abolished
the capability of RANKL to further bind to immobilized
RANK (Fig. 4B), confirming the role of decoy receptor for
OPG described in the literature. These results allow to explain
the OPG biological activity on osteoclasts through the for-
mation of a tertiary complex OPG–RANKL–RANK.4. Discussion
The molecular triad OPG–RANKL–RANK play a piv-
otal role in bone resorption regulation [7,9]. The results of
the present study demonstrate for the first time, that in
addition to be a decoy receptor for RANKL, OPG also
induces ras-MAPK activation on osteoclasts. Moreover, the
OPG-induced phosphorylations on osteoclast-like cells are
dependent on RANKL bound to the cell membrane, and
OPG–RANKL–RANK can constitute a hetero-molecular
complex as demonstrated by surface plasmon resonance
technique.
First evidence of an OPG binding on eucaryote cells was
given by Kwon et al. [18]. These authors identified a new
molecule named TNF receptor-like molecule 1 (TR1) which
exerted direct biological activities including osteoclasto-
genesis inhibition and fibroblast proliferation. In fact, this
molecule is identical to OPG. Scatchard analyses showed
two classes of high and medium affinity receptors for TR1
with kD of approximately 45 and 320 pM. More recently,
three different isoforms of the OPG-ligand, RANKL were
expressed in osteoblastic cells, two of them as transmem-
brane molecules and the third one, as a soluble protein [19].
If the expression of membrane-associated RANKL may
represent the specific high affinity ‘‘receptor’’ for OPG
reported by Kwon et al., the medium affinity receptors need
to be further characterized. Standal et al. [13] reported that
OPG can bind to heparan sulfate proteoglycans in myeloma
cells, evidencing a new potential binding molecule for OPG.
Proteoglycans have already been shown to mediate the
binding and the internalization of several extracellular
ligands [20] with affinity binding compatible to those
observed for TR1 [18]. Other experiments performed by
Reiland et al. [21] demonstrated that pervanadate activates
intracellular kinases leading to tyrosine phosphorylation of
syndecan-1. It has been proposed that cell surface proteo-
glycans as syndecans exert putative functions as growth
factor co-receptors, influencing the activation of various
tyrosine kinase receptor [22]. In light of the above data, it
can be suggested that OPG binds to membrane RANKL
and/or to cell surface heparan sulfate proteoglycans.
However, the mechanisms by which OPG exerts its
biological activity as well as the nature of its molecular
interactions with osteoclasts are not well defined. Hakeda
et al. [11] reported the first evidence of a direct biological
activity of OPG on isolated osteoclasts via a 140 kDa
OPG-binding protein. The exact nature of OPG receptors
on osteoclasts was not further characterized but RANKL,
as one putative OPG receptor has been evinced since it is
not expressed by osteoclasts. However, the production of
RANKL by contaminating stromal cells cannot be exclud-
ed. Direct biological activities of OPG on osteoclasts were
recently confirmed by Wittrant et al. [10] who demonstrat-
ed that in purified osteoclasts, OPG enhanced proMMP-9
activity among several other parameters (TRAP, TIMP,
cathepsin K). The present study reveals that OPG stim-
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pathway.
RAW264.7 cells differentiated in the presence of
RANKL, express osteoclast markers (RANK, TRAP, calci-
tonin receptor, cathepsin K) and allow to demonstrate the
OPG-induced ERK1/2 and p38 phosphorylations. Although
these cells did not express RANKL, blocking anti-RANKL
antibody totally abolished p38 activation and slightly re-
duced ERK1/2 activation, demonstrating OPG signaling
pathways dependent on RANKL. RANKL has been already
shown to induce specific signal transduction pathways in
osteoclasts through its binding to membrane RANK, espe-
cially p38 [16,23] and ERK1/2 [17,23]. In the RAW264.7
cells, soluble RANKL used to induce osteoclastogenesis is
bound to its receptor RANK present at the osteoclast cell
surface and OPG may bind to the preformed complex
RANKL–RANK, then re-inducing p38 activation. The
potential formation of a tertiary complex RANK–
RANKL–OPG is supported by the results of the surface
plasmon resonance studies, which revealed that OPG can
bind to the preformed complex RANKL–RANK. These
results allow to explain the direct OPG biological activity on
purified osteoclasts and differentiated RAW264.7 cells
through the formation of a hetero-molecular complex
OPG–RANKL–RANK (Fig. 3C). However, the slight
inhibition of OPG-ERK1/2 activation by an anti-RANKL
antibody suggests the potential existence of a second
binding site which is still undetermined. In this context,
proteoglycans such as syndecan-1 that can be phosphory-
lated by intracellular tyrosine kinase may be good candi-
dates ([21], Fig. 4C). In addition, OPG-induced MMP-9
activity on purified osteoclasts is abolished by a tyrosine
kinase inhibitor (Fig. 1), reinforcing this hypothesis. Re-
cently, Hotokezaka et al. [17] demonstrated that osteoclasto-
genesis is regulated under a balance between ERK and p38
pathways. In their system, ERK pathway negatively regu-
lates osteoclastogenesis while p38 pathway is involved as a
positive control. In our study, OPG-induced ERK1/2 phos-
phorylation independently of RANKL could strengthen the
specific inhibitory activity of OPG on osteoclastogenesis via
a similar balance [8].
Thus, OPG induces MAPK phosphorylation via RANKL
and acts as a decoy receptor. This dual function of OPG
could depend on its association sequence of both molecules.
Indeed, when OPG binds to RANKL before RANKL
binding to membrane RANK, it acts as a decoy receptor
(case of stromal cells which expressed membrane RANKL
but not RANK or soluble form of RANKL). In the case
where RANKL binds to RANK on osteoclast membrane
before its interaction with OPG, OPG could form a hetero-
tertiary complex on osteoclasts, therefore inducing MAPK
phosphorylations.
In conclusion, the present study demonstrated for the first
time that OPG stimulates proMMP-9 activity of osteoclasts
via the ras/MAPK pathway involving p38 and ERK1/2
phosphorylations. Moreover, OPG-induced MAPK pathwaydepends on RANKL. These data strengthened by the surface
plasmon resonance analyses suggest the potential formation
of a tertiary complex RANK–RANKL–OPG on osteo-
clasts. These overall results demonstrated that OPG is not
only a soluble decoy receptor for RANKL as described in
the literature but must be also considered as a direct effector
of osteoclast functions.Acknowledgements
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